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Mycobacterial infections—tuberculosis (TB), bovine tuberculosis (bTB), and Johne’s disease (JD)—are major infectious diseases
of both human and animals. Methods presently in use for diagnosis of mycobacterial infections include bacterial culture, nucleic
acid ampliﬁcation, tuberculin skin test, interferon-γ assay, and serology. Serological tests have several advantages over other
methods, including short turn-around time, relatively simple procedures, and low cost. However, current serodiagnostic methods
for TB, bTB and JD exhibit low sensitivity and/or speciﬁcity. Recent studies that have aimed to develop improved serodiagnostic
tests have mostly focused on identifying useful species-speciﬁc protein antigens. A review of recent attempts to improve diagnostic
test performance indicates that the use of multiple antigens can improve the accuracy of serodiagnosis of these mycobacterial
diseases. Mycobacteria also produce a variety of species-speciﬁc nonprotein molecules; however, only a few such molecules (e.g.,
cordfactorandlipoarabinomannan)havesofarbeenevaluatedfortheireﬀectivenessasdiagnosticantigens.ForTBandbTB,there
has been recent progress in developing laboratory-free diagnostic methods. New technologies such as microﬂuidics and “Lab-on-
Chip” are examples of promising new technologies that can underpin development of laboratory-free diagnostic devices for these
mycobacterial infections.
1.Introduction
Mycobacterial infections are a leading cause of health
concerns in humans and animals worldwide. Mycobac-
terium tuberculosis (MTB), Mycobacterium bovis (MB), and
Mycobacterium avium subspecies paratuberculosis (MAP) are
the causative agents of human tuberculosis (TB), bovine
tuberculosis (bTB), and Johne’s disease (JD), respectively.
In 2009, more than 9 million cases of TB were reported,
causing1.8milliondeaths[1].Multidrug-resistantTBstrains
and coinfections of TB and HIV are emerging problems
globally [2–4]. Despite much progress in eradicating bTB
in developed countries, this disease is responsible for US$ 3
billion economic losses globally [5] and remains prevalent in
some wild species [6, 7]. MAP is present in 68% of US dairy
herds [8], with JD responsible for an annual $220 million
economic loss to the US dairy industry [9].
Control measures for these mycobacterial diseases
revolve around understanding their epidemiology and
improving treatment/vaccination protocols; however, a
major bottleneck has been the lack of eﬃcient diagnostic
methods [2, 10–12]. Consequently, there would be much
beneﬁt to the development of rapid and accurate diagnosis
of TB at point-of-care [3] (In this paper, point-of-care diag-
nosis is deﬁned as diagnostic methods that can be conducted
on-site (e.g. ﬁeld, bed-side), with or without a requirement
for laboratory facilities. Laboratory-free (lab-free) diagnosis
is deﬁned as point-of-care diagnostic methods that does not
require any laboratory facility). Similarly, the most common
current diagnostic test for bTB, the tuberculin skin test
(TST), is not practical for controlling bTB in wild animals,
so a lab-free diagnostic device would also be helpful in this
context. Diagnosis of JD is currently conducted annually or
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device became available, it would reduce the long time
interval and cost of diagnosis. Thus, there would be a great
value in lab-free diagnostic technologies for TB, bTB, and JD
[13, 14].
Unfortunately, eﬃcient lab-free diagnostic devices for
these diseases are not yet available [14, 15]. Here, therefore,
we brieﬂy review currently available and recently developed
diagnostic methods for these three mycobacterial diseases
and highlight the potential beneﬁts of lab-free diagnosis.
Since serodiagnosis has been the most favored format for
development of lab-free diagnostic method, we focus in this
paper on methods of serodiagnosis over other diagnostic
methods such as bacterial culture and nucleic acid ampliﬁ-
cation that are necessarily laboratory based.
2. Human Tuberculosis
2.1. Background. Human tuberculosis (TB) is caused pri-
marily by MTB and occasionally by MB and M. africanum
(in this paper we focus on MTB). TB is a leading cause
of human morbidity and mortality throughout the world
[16]. One-third of the world’s population is infected by MTB
[1], although only 5–10% of infected individuals develop
an active, life-threatening form of the disease. In 2009,
9.4million cases of TB were reported with 1.8million deaths
worldwide [1, 2, 17].
Depending on the pathogenesis, infectivity, immune
response, and eﬀectiveness of treatment, TB can be divided
into 3 major forms. The ﬁrst is the active form of TB
(TBA), which results in a rapid development of clinical signs
in patients following contact with MTB. TBA develops in
only 5% of individuals infected with MTB; the remainder
develops a strong acquired immune response showing no
clinical signs, termed latent TB (TBL) [18]. The third
form is multidrug-resistant TB (MDRTB), which constitutes
approximately 5% of TBAs [19]. MDRTB is caused by
organisms resistant to, at least, isoniazid and rifampin [20].
The overall prevalence of MDRTB in developed nations is
much lower than that in developing nations, but can be
high in immigrant populations and among prisoners and
immunocompromised individuals [21, 22]. During the past
two decades, the emergence of HIV infection has led to
the recognition that TB/HIV coinfection promotes both the
reactivation of TBA from TBL and also the rapid progression
of primary TB following recent exposure to MTB [23].
Controlling TB depends on the following factors: case
detection, treatment of individuals with TBA, improving
anti-TB therapy to prevent resistance, identiﬁcation of TBL,
and better vaccination strategies for susceptible individ-
uals [16]. All these factors would beneﬁt from a better
understanding of the epidemiology of the TB infection [21]
and the development of more cost-eﬀective, evidence-based
approaches for its diagnosis [22]. Eﬃcient diagnosis of TB is
particularly important in third world nations that presently
lack adequate diagnostic resources at primary health care
centers. In these nations, TBL and MDRTB often remain
undiagnosed, which facilitates further transmission.
Presently, there are a number of alternative diagnostic
approaches towards diagnosis of TB and of TB coinfection
with other emerging infectious diseases; these are reviewed
brieﬂy here.
2.2. Imaging and Microscopic Techniques. Radiographic
imagingisstillwidelyusedtodiagnoseTB;however,thereare
no deﬁnitive diagnostic patterns, so that the method can be
used only for screening of TB cases. Further bacteriological
examinations are required for conﬁrmation [64, 65]. Smear
microscopy of stained sputum or other clinical material is
the most common test for TBA. This relatively inexpensive
method can be carried out rapidly in low-resource settings;
however, it lacks sensitivity and requires a large number
of bacilli (5,000–10,000 organisms/sample) [64, 66] in the
clinical specimen, which is often not the case in children,
advanced-stage TBA patients, and individuals coinfected
with HIV. Fluorescent microcopy is more sensitive, but its
application is limited by high cost and by issues relating to
the use of mercury vapor lamps in conventional ﬂuorescent
microscopes [67]. Nucleic acid ampliﬁcation (NAA) assays
have been found useful for diagnosis of TBA and MDRTB
infections, as they have high speciﬁcity and sensitivity and
can provide results within a few hours. Unfortunately, these
assays are costly, require a laboratory with trained staﬀ,
and suﬀer from poor speciﬁcity under ﬁeld conditions
[64, 68, 69].
2.3. Bacterial Culture and Cell-Mediated Immune-Response-
Based Testing. Bacterial culture is considered the gold stan-
dard for TBA diagnosis, having close to 98% speciﬁcity,
and is also useful in diagnosis of MDRTB. However, the
bacterial culture method suﬀers from low sensitivity (26–
42%), delayed results (6–8 weeks are required for culture
growth), a need for trained personnel and culture facilities,
and the high cost of the culture examination. The need
for technical expertise can be particularly problematic in
developing nations. Parsons et al. have recommended new
technologies including urine antigen detection, assays based
on volatile markers, bead-based, and ﬂow-cytometric-based
assays [3]—to help address these problems, but these assays
await optimization and establishment of clinical utility.
The tuberculin skin test (TST)—based on detection of
delayed-type hypersensitivity after an intradermal injection
of puriﬁed protein derivative (PPD) extracted from heat
killed MTB—has been in use for almost a century. The
primary roles of TST are to identify TBL individuals and to
monitor recent infection in high-risk groups. Some limita-
tions of TST include a high frequency of false reactions, the
need for a follow-up visit after 2-3 days of PPD inoculation,
misleading results due to confounding factors (e.g., age, HIV
infection, and infection with other mycobacterial species or
cancer), and positive reactions in TBA patients [64, 67, 70].
Based on the identiﬁcation of MTB-speciﬁc antigens using
molecular techniques, detection of cell-mediated immune
(CMI) response against MTB infection has improved the
diagnosis of TB. These assays measure the production of
cytokines (mainly interferon-gamma [IFN-γ]) produced by
T cells of MTB-infected individuals. Initial IFN-γ assays
were based on PPD antigen, but later the antigen was
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antigenic target (ESAT-6) and culture ﬁltrate protein (CFP-
10) [71]. IFN-γ assays do provide an improved diagnosis
of TBL; however, since they detect the presence of the
host’s CMI response towards MTB antigens, fresh blood
samples are required for the test. Inability to diﬀerentiate
between TBA and TBL, poor reproducibility, and reduced
eﬃcacy in children are additional problems of the CMI-
based diagnostic tests [72]. In developing countries, TST is
still preferred over IFN-γ assay due to its lower cost but
suﬀers from low eﬃcacy in children, poor reproducibility,
and reduced diagnostic accuracy for TBL [72–74].
2.4. Humoral-Immune-Response-Based Testing. In circum-
stances where medical resources (facilities and health care
providers) are limited, serodiagnostic methods for detec-
tion of anti-MTB antibodies have some advantages (i.e.,
simplicity, low cost, and requirement of minimum medical
resources) over aforementioned diagnostic methods [75].
Several target molecules (antigens) have been used to
detect the humoral responses (anti-MTB antibodies) in TB
patients. Early assays used PPD or other crude extracts as
antigens for capturing anti-MTB antibodies; however, these
showed poor speciﬁcity as dominant antibody responses
are against cross-reactive antigens (i.e., antigens commonly
found in MTB and also in other mycobacteria) [24]. As
molecular techniques have improved, many antigens have
been evaluated in serological tests, especially in the format
of the enzyme-linked immunosorbant assay (ELISA). Some
major antigens used in such tests are discussed below.
Antigen 5, also known as 38kDa antigen, is the best
studied and most available antigen for MTB diagnosis due
to its expression in the E. coli system. Many attempts
to develop an improved serological assay for TB have
used this antigen [30, 76]. Early studies reported 89%
sensitivity and 100% speciﬁcity in TBA patients [31]. Later
studies showed even higher sensitivity and demonstrated a
correlation between antibody level and bacterial load [77–
80]. As summarized in a review article [81], detection of
antibodies against Antigen85 complex in ELISA formats
achieves 50% sensitivity; however, this complex is highly
cross-reactive and often generates false-positive results in
individuals infected with atypical mycobacteria. A cell wall
component, called a cord factor (trehalose-6,6-dimycolate),
used as antigen in ELISA format achieved 84% sensitivity
with 100% speciﬁcity [32]. However, in a subsequent study,
it was shown that anticord factor antibodies decline after
antituberculous chemotherapy, which makes it diﬃcult to
determine the status of the infection in such patients [33].
Studies of the serodiagnostic potential of ESAT-6 [34, 35]
and CFP-10 [34, 35, 39, 40] have also been conducted.
One showed low sensitivity (67%) and speciﬁcity (51%)
for ESAT-6 [34]. Low sensitivity (48–63%) also has been
reported for CFP-10 [34,82].Inhighincidenceareas,neither
ESAT-6 nor CFP-10 antigens are useful in diﬀerentiating
b e t w e e nT B Aa n dT B L[ 34]. Another antigen, Kp 90, has
been used in ELISA format to detect IgA antibodies against
the protein; the results, when compared with NAA and other
serological assays, indicated that anti-Kp 90 antibodies were
detected in 78% of serum samples and 69% of samples from
synovial, cerebrospinal, and abscess body ﬂuids [41].
Antigen60(A60)isthemainthermostablecomponentof
PPD [83, 84]. Many studies have used this antigen and found
almost 100% speciﬁcity [42], with sensitivity ranging from
68 to 91% [43, 85]. Unfortunately, this molecule has also
beenfoundinnonpathogenicNocardia andCorynebacterium
species[83].A30kDaantigen(isolatedfromacultureﬁltrate
of MTB, Antigen 85B) was used in dot immunoassay, and
the result was compared with that of standard plate ELISA.
The speciﬁcities of the dot immunoassay and ELISA were
92% and 97%, respectively, and the sensitivities in the assays
were69%and78%,respectively[44].Furtherstudiesshowed
that this antigen not only diagnosed TBA but also detected
the nonprotective immune response of a healthy household
contact group [86].
Malate synthase (MS), a 81kDa protein (present in MTB
culture ﬁltrates, cell wall, and cytoplasmic subcellular frac-
tions) is an enzyme of the glyoxylate pathway used by MTB
during intracellular replication in macrophages [50]. Studies
with an MS-based assay have shown a sensitivity of 73% and
speciﬁcity of 98% in smear positive patients, suggesting that
MS is a potential candidate for TB diagnosis [82, 87]. The
cell wall of MTB also contains lipoarabinomannan (LAM);
however, its use as antigen in diagnostic tests is limited due
to immune complex formation [3]. LAM antigen is found in
urine of TBA patients, and tests based on detecting the LAM
in urine samples have been developed [46, 88, 89].
Steingart et al. conducted an intensive meta-analysis of
67studiespublishedin1990–2006oncommercialserological
tests for TBA (e.g., Detect-TB, and a-TB ELISA, ICT TB test)
[75]. Antigens used in the commercial tests include Antigen
60, 38-Kda protein, LAM, and Kp-90. The meta-analysis
revealedthatestimateddiagnosticsensitivities(0–100%)and
speciﬁcities (31–100%) in the studies were inconsistent and
imprecise, which is consistent with a WHO report in 2008
[90].
In patients coinfected with HIV and MTB, the level of
antibody production to TB antigens diﬀers from that of
HIV-negative TB patients. For example, an ELISA based on
MS/MPT51 antigens showed positive reactions in approx-
imately 80% of HIV-positive, TB-positive patients and in
42% of HIV-negative, TB-positive patients [51]. Wanchu
suggested that better diagnosis of TB will require a focus on
development of multi-antigen-based tests and identiﬁcation
of novel MTB proteins that increase in HIV patients [91].
2.5. Point-of-Care Diagnosis and Future Directions. The
studies described above indicate the need for an improved
d i a g n o s t i ct e s tt h a ti sb e t t e ra b l et od i ﬀerentiate the three
forms of TB infection and to diagnose TB in the presence
of HIV infection. Furthermore, since most deaths due to TB
occur in developing countries that lack proper laboratory
facilities and specialist training, it is important to develop
a simple, rapid, and cost-eﬀective test. The Xpert MTB/RIF
assay has been recently used as point-of-care diagnosis for
MDRTB and drug-sensitive TB [92, 93]. Although simple
to perform and highly sensitive, this assay is costly [94].
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point-of-care diagnosis [95] and suggest three important
areas in which progress should be made to achieve better
point-of-care for TB. The ﬁrst is through identiﬁcation of
biological, metabolic, and pathogen-derived markers that
will assist in understanding the disease. The second is the
development of eﬀective technologies like immunochro-
matography and nanotechnology. The third is to better
understand the economical and logistic constraints on the
implementation of new tests [95]. In summary, there is an
urgent need to develop a lab-free diagnostic device for TB
that will decrease disease transmission rate, reduce death
rates, and permit faster initiation of treatment.
3.BovineTuberculosis
3.1. Background. Bovine tuberculosis (bTB), caused by
Mycobacterium bovis (MB), is an infectious, chronic but pro-
gressive disease characterized by the formation of granulo-
matouslesionswithvaryingdegreesofnecrosis,calciﬁcation,
and encapsulation [11]. MB is known to infect and cause
tuberculosis in a wide range of wild animals, livestock ani-
mals,andhumans.AlthoughbTBhasbeenmostlyeradicated
in the livestock industry of developed countries, the disease
inwildlifestillposesarisktolivestock,tourismeconomy,and
wildlife conservation [11]. Infected wildlife species include
white-tailed deer (Odocoileus virginianus) in several states of
the USA, Eurasian badgers (Meles meles) in Great Britain and
the Republic of Ireland, and brushtail possums (Trichosurus
vulpecula) in New Zealand [6]. Global economic losses from
bTB total US$ 3 billion annually [5]. In the USA, US$
40million and in Great Britain £100 million were spent
on bTB management in the year 2008-2009 alone [5]. In
developing countries, bTB still causes serious concerns not
only for wildlife, but also for public health, food safety, and
the economy of livestock industries. More accurate diagnosis
of bTB would reduce the unnecessary sacriﬁce of healthy
animals and would also help to more eﬀectively control bTB.
At present, postmortem diagnosis based on examination
of gross lesions, followed by histopathology and culture, is
widely used for surveillance of bTB in wild animals, but this
method is time-consuming and cannot diagnose an early
infection [96].
3.2. Cell-Mediated Immune-Response-Based-Testing. The
ante mortem diagnostic method currently prescribed by
OIE is the intradermal tuberculin skin test (TST) [97]. The
TST is by far the most eﬀective test used in the eradication
of bTB in the developing countries. The test is performed
by injecting a small volume of bovine tuberculin in the
skin of the animal and palpating a change in the thickness
of the skin at the site of injection after 48–72 hours. The
tuberculin used in most of the countries is derived from
cultures of MB AN5, a ﬁeld strain isolated in England circa
1948 [5, 26, 96]. The TST is, however, susceptible to causing
false-positive reactions due to exposure of some animals to
environmental mycobacteria such as M. avium and MAP
[96, 98–100]. TST can also cause false-negative reactions due
to immunosuppression, desensitization towards tuberculin,
subpotent use of tuberculin, and lengthy exposure to a ﬁeld
strain [96]. Steps have been taken to improve speciﬁcity by
using speciﬁc antigens, such as ESAT-6 [101] and a cocktail
of ESAT-6/CFP-10/MPB83; however, these studies still need
to be validated at a larger scale [5].
Revisiting the animal after 2-3 days application of the
TST to check their reaction is labor intensive (and usually
impractical for free-ranging wildlife). The alternative IFN-
γ assay is an in vitro blood test based on measuring the
CMI response of the animals infected with MB [102]. The
IFN-γ assay is usually performed using PPD as antigen,
although recent studies have evaluated ESAT-6 and CFP-
10 [103–106]. A problem with the IFN-γ assay is that it
is a costly process that requires well-trained personnel to
carry out the test [26, 107]. Bacteriological culture of clinical
samples (i.e., milk, blood, nasal swab, and cattle tissues) is
considered to be the gold standard for bTB diagnosis but,
the test requires a minimum of several weeks [96, 108].
Nucleic acid ampliﬁcation methods (e.g., PCR) have been
also used for bTB diagnosis, but these methods are costly,
less sensitive than the bacteriological culture test and again
require a trained technician to perform the test [96, 108–
110].
3.3. Humoral Immune-Response-Based Testing. Another type
of immunological test is based on detection of humoral
immune response (i.e., antibody production). The major
advantages of the antibody-detection tests are that they are
inexpensive and relatively easy to perform. However, low
sensitivity of the antibody-detection tests remains a concern.
Several attempts have been made to develop ELISA tests
for detection of antibody response against MB infections.
PPD was used as an antigen to measure antibody response
in animals with MB infection [111, 112], but the cross
reactivity of PPD with closely related mycobacterial species
has always been a concern. Auer [113] used a sonicated
preparation of MB as antigen and reported low speciﬁcity
[113]. Further studies used a speciﬁc protein isolated from
MB bacillus Calmette-Guerin (BCG) strain, MPB70, as an
antigen for developing assays for the diagnosis of bTB. The
use of MPB70 achieved better speciﬁcity (96.4%) but had
poor sensitivity (18.1%) [114–116]. Ag85 complex consists
of the major secretion products of MB BCG strain and
has 3 major components: 85A (31kDa), 85B (30kDa), and
85C (31.5kDa). This complex is strongly immunogenic and
has been used for the development of assays to diagnose
TB and bTB. However, low sensitivity was reported from
studies using Ag85 in ELISA format and attributed to false-
positive reactions caused by infections with environmental
mycobacteria [54, 81, 115]. MPB83 has been used as antigen
in many studies and is a very promising candidate for bTB
serodiagnosis [53]. As discussed in the TB section, LAM,
ESAT-6, and CFP-10 have also been used as antigens to
detect antibody response against MB [117–122]. Further,
as molecular biology tools have improved, recombinant
proteins have come to be used as antigens for diagnosis of
bTB. Since recombinant proteins can be produced at large
scale, they are cost-eﬀective and provide consistency in their
quality as diagnostic antigen [55, 123, 124].Veterinary Medicine International 5
3.4. Point-of-Care Diagnosis and Future Directions. One
of the promising antibody-based detection assays, Multi-
Antigen Print Immuno-Assay (MAPIA), is based on immo-
bilization of antigens onto nitrocellulose membranes by
semiautomated microspraying, followed by standard chro-
mogenic immune development. This serodiagnostic test uses
a cocktail of multi-antigens, such as MPB83/70, ESAT-6, and
CFP10 [36] .I nar e c e n ts t u d y ,s e r o r e a c t i v i t yw i t hM P B 8 3i n
deer was 89%; however, MAPIA showed that 26% of these
were false positives [37]. Based on these MAPIA results,
an e wv e r s i o no fa ni m m u n o c h r o m a t o g r a p h i ct e s tf o r m a t
for rapid diagnosis of MB infection, called rapid test (RT),
was developed using colloidal gold conjugated to protein
A. RT uses recombinant proteins of MPB83 and TBF10
printed onto a membrane either separately as two bands or
as a combination of the two antigens in one test line [56].
Diagnostic sensitivity of the RT in experimentally infected
deer was 79%, whereas that in naturally infected deer was
67% [37]. Jaroso et al., [125] compared the RT with the
comparative cervical skin test (CCT) and found similar
sensitivities of 80.1%. They also found that by combining the
results from both RT and CCT, the sensitivity was 100%. It
was suggested that the combined uses of RT and CCT would
maximize sensitivity of bTB detection [125]. Some recent
studies have concluded that ESAT-6 and CFP10 (used either
individuallyorascocktail)arebettercandidatesfordiagnosis
of bTB [126–128].
MAPIA and RT can be conducted in ﬁeld situations
and so can contribute to eﬀective testing/control of bTB,
especially in wild animals. However, interpretation of the
test results in MAPIA and RT relies on observation of color
developmentonastrip,whichmayvarydependingonexam-
iners. Higher accuracy and consistency could be achieved
via a lab-free diagnostic device that outputs numerical data
basedonlevelofantibodybindingtoMBantigen(s).Further,
as we discussed above, eﬀort needs to be directed towards
identifying a better antigen (or a combination of antigens) to
further improve diagnostic sensitivity and speciﬁcity.
4.Johne’s Disease
4.1.Background. Johne’sdisease(JD)orparatuberculosisisa
chronic infectious enteritis of domestic and wild ruminants,
causing reduction in milk production, malnutrition, weight
loss, and eventually death [129, 130]. JD is prevalent
worldwide and has a signiﬁcant impact on global animal
husbandry. In the USA, the causative agent of JD, Mycobac-
terium avium subsp. paratuberculosis (MAP), is found in
68% of dairies [8], with average herd-level prevalence of
JD estimated to be 22%. The annual loss in the US dairy
industrycausedbyMAPinfectionhasbeenestimatedat$220
million [9]. Economic losses associated with JD arise from
decreased milk production, reduced fertility, and higher rate
of culling [131]. In addition to the economic impact of JD to
dairy industry, it is possible that MAP plays a role in Crohn’s
disease, which is an inﬂammatory bowel disease in humans
[132]. These economic and possible health concerns create
an urgent need for improved control of JD. As no practical
treatment is available for JD, a better understanding of the
transmission, detection, and management of the disease are
the recommended procedures for its control [133].
4.2. Bacterial Culture and Cell-Mediated Immune-Response-
Based Testing. Diagnostic tests to detect infection with MAP
can be categorized as those that identify the organism
and those that identify the immunological response to the
organism. Fecal culturing for MAP using Herrold’s egg yolk
medium (HEYM) has been considered as a gold-standard
test for JD diagnosis; however, it takes as long as 16 weeks
to see an observable growth. Other approaches, such as the
use of BACTEC radiometric liquid culture [134, 135]a n d
MGIT culture medium [136], have been examined to reduce
the culture time but these approaches require a specialist and
are relatively expensive. Polymerase-chain-reaction- (PCR-
) based diagnosis using IS900 insertion sequence [137],
HspX [138], or F57 DNA fragment [139], on the feces of
suspect animals can also be used. This PCR-based approach
is much faster but is less sensitive than the culture test
because PCR reaction can be inhibited by substances in the
feces. Animals develop both CMI and humoral responses
against MAP. A CMI-based diagnostic test, the IFN-γ assay,
has been evaluated using blood samples of experimentally
infected cattle. The study demonstrated that the IFN-γ assay
could detect MAP infections in early stage of JD [140, 141];
however, IFN-γ assay is aﬀected by antigen stimulation and
blood sampling-storage conditions [142, 143]. This suggests
that the IFN-γ test requires further optimization.
4.3. Humoral Immune-Response-Based Testing. Three diﬀer-
ent tests are used to measure antibody response in JD:
complement ﬁxation, agar gel immunodiﬀusion, and ELISA.
Thecomplementﬁxationandagargelimmunodiﬀusiontests
both suﬀer poor sensitivity [144], and so a recent report
has suggested that ELISAs are the best of the three methods
for controlling JD in dairy and beef herds [133]. Diagnoses
of JD using ELISA have been reported in many previous
studiesusingdiﬀerentantigens[28,29,48,63,141,145–151].
The antigens used in these studies have used protoplasmic
antigen (PPA) [28, 29, 146, 147, 149, 150], lipoarabinoman-
nan (LAM) [48], culture ﬁltrate of MAP [63], and MAP
proteins-1152 and 1156 [151] for testing antibodies against
MAP. Beam et al. described a crude antigen mixture termed
PPA, which is prepared by thorough physical disruption of
mycobacterial bacilli followed by removal of cell debris and
cell wall components [152]. Although many investigators
have prepared PPA using various preparation protocols, it
contains proteins very similar to proteins commonly found
in closely related mycobacteria species. LAM is one of the
components of the cell wall of mycobacteria species [120],
and its core structure is shared among mycobacterial species
[153].
Sweeney et al. tested milk and serum samples in an
LAM-based ELISA to detect antibodies for JD diagnosis
and found that sensitivity and speciﬁcity of the ELISA were
similar regardless of the tested samples (i.e., milk and serum)
[48]. McKenna et al. [49] compared diagnostic performance
of PPA-based ELISA and LAM-based ELISA using fecal6 Veterinary Medicine International
culture test as a gold standard. Sensitivity and speciﬁcity of
the PPA-based ELISA were higher than that for the LAM-
ELISA [49]. PPA and LAM both contain structures common
in mycobacterial species, so the use of these molecules
as diagnostic antigen can cause false-positive reactions in
animals infected with environmental mycobacteria other
than MAP [154].
Bannantine etal.tested18 puriﬁed recombinant proteins
in ELISA format for serodiagnosis of ovine paratuberculosis.
They found that MAP proteins 0862 and 3786 demonstrated
the strongest antibody response and MAP protein 2116c the
weakest [58]. Shin et al. used culture ﬁltrate of an MAP
strain, JTC, in ELISA format for JD diagnosis and named the
method JTC-ELISA [63]. JTC-ELISA showed signiﬁcantly
higher sensitivity (56.3%) than that of commercial ELISA
tests (28–44%) and performed eﬀectively on both serum
and milk samples. As mentioned above, the recommended
control measure for JD is testing herds by ELISA methods
but the current ELISA tests have low sensitivity (28–44.5%)
[29].Wehavepreviouslyreportedthatthesurfaceantigensof
MAP are capable of detecting anti-MAP antibodies in serum
at early stages of JD [59, 60]. Since mycobacteria are known
to express species-speciﬁc lipidic molecules on their surface,
surface antigens were extracted by gently mixing MAP with
various organic solutions and tested for antibody binding in
ELISA format [61]. Antigens extracted from MAP by using
80% ethanol showed the greatest diﬀerentiation between
antibody binding in JD-negative and JD-positive serum
samples [61]. An ELISA test developed using the ethanol
extract has been named ethanol vortex ELISA (EVELISA).
The results from EVELISA showed that 98.4% of the JD-
positive samples had higher antibody binding levels than
those of JD-negative samples, whereas the percentage of
positive antibody binding in a commercial ELISA test was
50% [61]. By using thin layer chromatography, species-
speciﬁclipidic moleculesweredetectedintheethanolextract
(unpublished data). Eckstein et al. reported that species-
speciﬁc antigenic lipopeptides (e.g., Para-LP-01) exist on
the surface of MAP [155], and the high sensitivity of the
EVELISA may be attributed to these lipopeptides.
E L I S A ,a sw e l la so t h e rm e t h o d sf o rJ Dd i a g n o s i s ,
needs to be conducted in diagnostic laboratories employing
staﬀ with expertise in microbiology, molecular biology,
and immunology. This requires a labor-intensive process
involving collecting samples into proper containers, index-
ing, packing, and shipping. Furthermore, cost per sam-
ple is relatively high—testing a sample by current fecal
culture, PCR, and ELISA tests cost $16–19, $25, and $5-
6, respectively, and this does not include costs associated
with site visits and sample collections and shipping [133].
Because of the labor and cost for the current JD diagnosis,
screening of cattle herds for JD is generally conducted at an
interval of 6–12 months. During this interval, nonshedding
animals can become shedders and low-shedding animals can
become high shedders, thereby spreading MAP infection
widely in the herd. This relatively long time interval between
JD screening tests, in combination with low sensitivity of
current diagnostic tests, may have been a reason that MAP
infections remain so widespread in the US dairy and beef
industries.
4.4. Point-of-Care Diagnosis and Future Directions. Control-
ling JD requires a better understanding of the spread of
MAP in a dairy herd, which can be achieved by continuous
monitoring of the infection using a lab-free diagnostic
device. For development of a lab-free diagnostic device,
microﬂuidic technology has begun to be employed in the
last decade [15]. Microﬂuidic devices are state-of-the-art
tools for biochemical and immunological analysis that have
high sensitivity, require only short periods of time, small
amounts of reagents, and do not require an expert operator
[13, 14, 156]. In our recent study, we developed a prototype
of lab-free diagnostic device for JD by using a microﬂuidic
technology and the antigen used in the EVELISA test [157].
The device is composed of microﬂuidic channels/chamber
with electrodes, light source for ﬂuorescence excitation, and
light detector. The EVELISA antigen was immobilized in the
microchannel and reacted sequentially with bovine serum
sample and ﬂuorescently labeled secondary antibody. Liquid
ﬂow was controlled by applying AC signals to the electrodes
in the microchannel. Further, antibody-antigen interaction
was accelerated by creating liquid vortices by applying AC
signals to the reaction chamber. The major advantages of
this system are its low cost, ultraportable, and disposable
immunoreactions chip, and the ability to detect antibodies
within 20min [157].
5. Conclusion
Among the diagnostic methods used for TB, bTB, and JD,
serological methods have some compelling advantages that
include short turn-around time, simple procedure, and low
cost.However,assummarizedinTable 1,previousreportson
serodiagnosis indicated a lack of diagnostic accuracy and/or
insuﬃcient-tested samples for validation of the estimated
diagnostic accuracy. The low diagnostic accuracy of the cur-
rent serodiagnosis for the mycobacterial infections may be
due to the false-positive reactions (causing low speciﬁcity),
arising from exposure of some tested individuals to other
nonpathogenic environmental bacteria. Recent studies have
indicated that the use of multiple species-speciﬁc antigens
may improve diagnostic accuracy of the serodiagnosis of the
mycobacterial diseases. Some nonprotein molecules (cord
factor and lipoarabinomannan) were also evaluated for sero-
diagnosisofmycobacterialinfections.Sincemycobacteriaare
known to produce a variety of species-speciﬁc non-protein
molecules, further eﬀorts to identify non-protein diagnostic
antigens may be a useful contribution to the development of
more speciﬁc tests for TB, bTB, and JD.
Most, if not all, of the current diagnostic tests for
mycobacterial infections are carried out in a diagnos-
tic laboratory, causing cost for sample processing and/or
long turn-around time. Lab-free diagnostic devices would
be valuable in understanding the epidemiology of the
mycobacterial infections and would facilitate their control.
The emergence of new technology, microﬂuidic lab-on-a-
chip (LOC), holds considerable promise for acceleratingVeterinary Medicine International 7
Table 1: Summary of humoral immune response based assays.
Target antigen MTB/MB/MAP Method of testing Se (%) Sp (%) PN Species tested Reference
PPD MTB ELISA 89 87 18 83 Human [24, 25]
PPD MB ELISA 68–95 96–99 120 223 Cattle [26, 27]
PPD MAP ELISA 29–72 99 359 2094 Cattle [28, 29]
Antigen 5 (38kDa) MTB ELISA 89 94–100 82 30 Human [30, 31]
Cord factor MTB ELISA 81–84 96–100 65 66 Human [32, 33]
ESAT-6 MTB ELISA 67 51 100 100 Human [34, 35]
ESAT-6 MB ELISA 49–59 84–95 522 1489 Cattle [36–38]
ESAT-6 MB MAPIA 67 98 9 98 Deer
CFP-10 MTB ELISA 48–63 51–71 100 100 Human [34, 39, 40]
CFP-10 MB ELISA 49–59 84–95 522 1489 Cattle [36–38]
CFP-10 MB MAPIA 56 99 9 98 Deer
Kp90 MTB ELISA 78 82 51 71 Human [41]
Antigen 60 MTB ELISA 68–91 100 337 131 Human [42, 43]
30kDa antigen MTB ELISA 84 96.7 175 150 Human [44, 45]
LAM MTB ELISA 17.8 87.7 47 153 Human
[27, 46–49] LAM MB ELISA 60 na 120 — Cattle
LAM MAP ELISA 66 88 167 216 Cattle
MS MTB ELISA 73–75 97-98 35 17 Human [50–52]
MPT51 MTB ELISA 80 na 53 — Human [51]
MPB70 MB ELISA 73 88 120 223 Cattle [27, 36–38, 53]
MPB70 MB MAPIA 44 100 9 98 Deer
Antigen 85 complex MB ELISA 48 89 208 54 Cattle [54, 55]
MPB 83 MB ELISA 49–59 84–95 522 1489 Cattle [36, 53, 56]
MPB83 MB MAPIA 89 99 9 98 Deer [36–38, 53, 56, 57]
MPB83 MB RT 60 96 25 25 Cattle
MAP proteins 0862 and
3786 MAP ELISA 81 na 11 — Sheep [58]
Ethanol extract MAP ELISA 97.4 100 64 38 Cattle [59–62]
JTC MAP ELISA 56.3 99 444 412 Cattle [63]
Se, Sensitivity; Sp, Speciﬁcity; P, no. of positive samples tested; N, no. of negative samples tested.
the development of lab-free diagnostic devices for these
mycobacterial infections. LOC refers to miniaturized devices
that can perform single or multiple laboratory procedures
on a chip with a footprint of only a few inches in size
[158]. Various LOCs have been developed for biochemical
assays,detectionofsmallparticles(cellsandbacteria),single-
cell analysis, immunoassays, and so forth. Because of its
small size and capability of automation, the technology
oﬀers opportunities for the development of point-of-care
diagnostic devices for various diseases and physiological
conditions. In the last decade, LOC technology has been
employed for development of antibody detection assays
[159, 160]. The principle of the immunoassay is same
as conventional serological tests—detection of antibody
binding to immobilized diagnostic antigen. However, whole
assay processes (antibody reaction, washing, and detection)
are carried out in a microﬂuidic system (microchannels).
Liquid ﬂow in the microchannel is controlled by electric
ﬂuid handling, pressure-driven ﬂuid handling, or passive
capillary force ﬂuid handling [160]. Detection of antibody
binding in LOC is based on either optical or nonoptical
detection methods [159]. The most common types of
optical detection systems are ﬂuorescence detection and
surface plasmon resonance. Fluorescence detection is highly
useful technique due to its high sensitivity and the ease of
integrating a label to the marker [159]. Surface plasmon
resonancetechnologyisbasedonmeasurementofthechange
in plasmon mode due to binding of biomolecules (antibody)
to the surface (immobilized antigen) [161]. The nonopti-
cal detection system is based mainly on measurement of
change in the electrochemical properties due to molecular
interactions on the reaction surface. This approach (i.e.,8 Veterinary Medicine International
a label-free sensor) does not require cumbersome detection
system and therefore makes the LOC device relatively small
and inexpensive [161]. Although development of lab-free
diagnostics for mycobacterial diseases is in its infant stage,
a recent study demonstrated the detection of MTB using
ﬂuorescentmarkers [95,162].Also,werecentlyreportedthat
a prototype of LOC-based system could detect antibodies
in JD-positive serum in 20min [157]. Further, the system
was converted to a label-free system using an electrochemical
detection,reducingthedetectiontimeto2min(unpublished
data).
A combination of species-speciﬁc (multi) antigens and
LOC technology may lead to development of an accurate
on-site (in-ﬁeld) diagnostic device and thereby contribute to
eﬀective control of mycobacterial infections.
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